PACT Pharma is a biotechnology company that develops personalized adoptive cell therapies designed for the eradication of solid tumors.
PACT Pharma focuses on re-programming immune system to target and to eradicate the cancer.
PACT Pharma was founded in 2016 by Jim Heath, Toni Ribas and David Baltimore. The company is headquartered in South San Francisco, California.
PACT’s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer.
PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient’s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens.
PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient’s own blood to produce PACT’s therapeutic product.
PACT is backed by GV (formerly Google Ventures), Vida Ventures, Canaan Partners, Casdin Capital, Droia, Foresite Capital and others. The company raised $75M in a Series C financing on Jan 13, 2020. This brings PACT's total funding to $200M to date.